GLTO
Damora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.58
−3.36%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -24.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +80.0%
- Free cash flow
- +63.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026